Washington Paid Clinical Trials

A listing of 1729 clinical trials in Washington actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Clinical Trials

Washington

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Location

Filter by Age

Washington is currently home to 1729 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Seattle, Spokane, Tacoma and Vancouver. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.

Featured Trial

Healthy Participants Needed (Colonoscopy + Cancer Screening)

Recruiting

Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.

Conditions:

Healthy

Healthy Volunteers

Healthy Subjects

Healthy Volunteer

Healthy Participants

Learn More

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

Featured Trial

Buy Retatrutide Online Through Celia

Recruiting

Retatrutide (formerly M25) is an investigational peptide being studied for its potential in supporting weight management and metabolic health. It acts on GLP-1, GIP, and glucagon receptors to influence appetite, energy regulation, and fat metabolism.

Conditions:

Healthy

Learn More

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Featured Trial

Depression Clinical Trial

Recruiting

Join us in researching a potential investigational treatment for Depression. Reimbursement for study-related expenses may be available to you.

Qualifying participants:
•Are between 18-65
•Have been experiencing a major depressive episode for at least a month

Conditions:

Depression

Major Depressive Disorder

Depressive Disorder

Depressive Symptoms

Depressive Disorder

Learn More

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

NCT06129864

Recruiting

The main purpose of this study is to assess the efficacy and safety of volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) who have not progressed after receiving definitive concurrent chemoradiotherapy (cCRT).

Gender:

ALL

Ages:

Between 18 years and 130 years

Trial Updated:

07/29/2025

Locations: Research Site, Spokane, Washington

Conditions: Locally Advanced Head and Neck Squamous Cell Carcinoma

Learn More ›

Positive Processes and Transition to Health (PATH)

NCT06093906

Recruiting

The R33 will be a randomized controlled trial to replicate changes in the targets (unproductive processing, avoidance, reward deficits) from the R61 phase in a larger sample of 135 participants who have experienced a destabilizing life event involving profound loss or threat, report persistent stressor-related symptoms of PTSD and/or depression, and are elevated on symptoms related to 2 of the 3 therapeutic targets. Additionally, this study will examine Positive Processes and Transition to Healt... Read More

Gender:

ALL

Ages:

Between 18 years and 65 years

Trial Updated:

07/29/2025

Locations: University of Washington, Seattle, Washington

Conditions: Posttraumatic Stress Disorder, Major Depressive Disorder

Learn More ›

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults

NCT06047457

Recruiting

The purpose of this study is to understand the safety and effectiveness of the study drug, Dysport® when compared with placebo in preventing episodic migraine. A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head, and is often accompanied by feeling or being sick and a sensitivity to bright lights and sound. Episodic Migraine is defined as having less than 15 days of headache a month with at least 6 days with migraine headaches. Migraines are caused by a series of events which cause the brain to get stimulated / activated, which results in the release of chemicals that cause pain. Dysport® is a formulation of Botulinum toxin type A (BoNT-A), a medication that stops the release of these chemical messengers. The study will consist of 3 periods: 1. A 'screening period' of 6 to 12 weeks to assess whether the participant can take part to the study and requires 1 visit. 2. A first Treatment Phase of 24 weeks. On Day 1 and at Week 12 of the first Treatment Phase, participants will receive injections into various muscles across the head, neck, face and shoulders. The injections will contain either a dose "A" or a dose ''B'' of Dysport® or a placebo (an inactive substance or treatment that looks the same as, and is given in the same way as, an active drug or intervention/treatment being studied). Participants will make 4 visits to the clinic in person and have 4 remote (online) visits. 3. A second Treatment Phase of 24 weeks (extension phase). At Week 24 and at Week 36, all participants will get Dysport® (dose "A" or dose "B"). There will be 3 in person visits and 4 remote visits. Participants will need to complete an e-diary and questionnaires throughout the study. Participants will undergo blood samplings, urine collections, physical examinations, and clinical evaluations. They may continue some other medications, but the details need to be recorded. The total study duration for a participant will be up to 60 weeks (approx. 14 months). Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/29/2025

Locations: MedStar Health - Department of Neurology, Columbia, Washington

Conditions: Episodic Migraine

Learn More ›

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults

NCT06047444

Recruiting

The purpose of this study is to understand the safety and effectiveness of the study drug, Dysport® when compared with placebo in preventing chronic migraine. A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head, and is often accompanied by feeling or being sick and a sensitivity to bright lights and sound. Chronic migraine is defined as having at least 15 days of headache a month with at least 8 of those days being migraine headache days. Migraines are caused by a series of events which cause the brain to get stimulated/activated, which results in the release of chemicals that cause pain. Dysport® is a formulation of Botulinum toxin type A (BoNT-A), a medication that stops the release of these chemical messengers. The study will consist of 3 periods: 1. A 'screening period' of 6 to 12 weeks to assess whether the participant can take part to the study and requires 1 visit. 2. A first Treatment Phase of 24 weeks. On Day 1 and at Week 12 of the first Treatment Phase, participants will receive injections into various muscles across the head, neck, face and shoulders. The injections will contain either a dose "A" or dose "B" of Dysport® or a placebo (an inactive substance or treatment that looks the same as, and is given in the same way as, an active drug or intervention/treatment being studied). Participants will make 4 visits to the clinic in person and have 4 remote (online) visits. 3. A second Treatment Phase of 24 weeks (extension phase). At Week 24 and at Week 36, all participants will get Dysport® (dose "A" or dose "B"). There will be 3 in person visits and 4 remote visits. Participants will need to complete an e-diary and questionnaires throughout the study. Participants will undergo blood samplings, urine collections, physical examinations, and clinical evaluations. They may continue some other medications, but the details need to be recorded. The total study duration for a participant will be up to 60 weeks (approx. 14 months). Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/29/2025

Locations: MedStar Health - Department of Neurology, Columbia, Washington

Conditions: Chronic Migraine

Learn More ›

A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis

NCT06016842

Recruiting

The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) and cirrhosis (scarring of the liver). PBC is a slowly progressive disease, characterised by damage to the bile ducts in the liver, leading to a build-up of bile acids which causes further damage. The liver damage in PBC may lead to cirrhosis. PBC may also be associated with multiple symptoms. Many patients with PBC may require liver transplant or may die if the disease progresses and a liver transplant is not... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/29/2025

Locations: Medstar Georgetown Transplant Institute University Hospital (MGUH), Columbia, Washington

Conditions: Primary Biliary Cholangitis (PBC)

Learn More ›

A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus

NCT06013995

Recruiting

The purpose of this study is to evaluate safety, drug levels and drug effects on cells and organs of the body, after receiving multiple increasing doses of BMS-986326 via intravenous (IV) infusion or subcutaneous (SC) injection, in participants with different forms of lupus.

Gender:

ALL

Ages:

Between 18 years and 75 years

Trial Updated:

07/29/2025

Locations: Arthritis Northwest, PLLC, Spokane, Washington

Conditions: Lupus

Learn More ›

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

NCT05806515

Recruiting

This phase II trial tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping, or slowing the growth of tumor cells. Giving carboplatin before surgery may shrink tumors in patients with h... Read More

Gender:

MALE

Ages:

18 years and above

Trial Updated:

07/29/2025

Locations: Providence Regional Cancer System-Aberdeen, Aberdeen, Washington

Conditions: Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8

Learn More ›

Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)

NCT05776069

Recruiting

The VIVID study is structured in a master protocol format comprised of multiple parts that evaluate intravenous (IV) and subcutaneous (SC) VGA039 in healthy volunteers and subjects with von Willebrand Disease (VWD) and other bleeding disorders.

Gender:

ALL

Ages:

Between 12 years and 60 years

Trial Updated:

07/29/2025

Locations: Washington Center for Bleeding Disorders, Seattle, Washington

Conditions: Von Willebrand Diseases

Learn More ›

Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder

NCT05303064

Recruiting

To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine

Gender:

ALL

Ages:

Between 10 years and 17 years

Trial Updated:

07/29/2025

Locations: Alkermes Investigator Site, Everett, Washington

Conditions: Schizophrenia, Bipolar I Disorder

Learn More ›

Evolut™ EXPAND TAVR II Pivotal Trial

NCT05149755

Recruiting

Obtain safety and effectiveness data to support indication expansion for the Medtronic TAVR System to include patients with moderate, AS.

Gender:

ALL

Ages:

65 years and above

Trial Updated:

07/29/2025

Locations: Providence Sacred Heart Medical Center & Children's Hospital, Spokane, Washington

Conditions: Moderate Aortic Valve Stenosis

Learn More ›

DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)

NCT04567420

Recruiting

A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)

Gender:

ALL

Ages:

All

Trial Updated:

07/29/2025

Locations: Swedish Cancer Institute, Seattle, Washington

Conditions: Breast Cancer

Learn More ›

Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

NCT00271180

Recruiting

The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.

Gender:

ALL

Ages:

All

Trial Updated:

07/29/2025

Locations: Not set, Olympia, Washington

Conditions: Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia

Learn More ›